Genomeditech(Shanghai) Co.LTD

Where Discovery Begins

Free Shipping for In-Stock Functional Cell Line

Leave Your Comment & Get 20% Off

Share Your Cell Line Experience. Get Rewarded.

Contact Us

EN

Insights

Press Release

Current position：News > Insights

Insights

CDH17: The Next Emerging Target in Gastrointestinal Cancer Therapy

Discover how CDH17 is emerging as a promising target in gastrointestinal cancer therapy and shaping the future of precision oncology.

BDCA2: The Next Frontier in Lupus Drug Development

By modulating plasmacytoid dendritic cell (pDC) activity and regulating type I interferon signaling, BDCA2-targeted therapies are opening new possibilities for autoimmune disease treatment.

CD117: A Classic Therapeutic Target Regaining Attention

Explore how CD117 (c-KIT), a classic therapeutic target, continues to inspire new research opportunities in the evolving landscape of drug discovery.

OX40/OX40L: Emerging Opportunities in Next-Generation Immunotherapy

Explore the emerging role of the OX40/OX40L signaling axis in next-generation immunotherapy, including its mechanisms of immune regulation, therapeutic potential, and evolving clinical landscape across oncology and autoimmune diseases.

CD79b: From ADC Success to the Next Frontier of Multimodal Immunotherapy

CD79b, once regarded primarily as an ADC target in B-cell malignancies, is now emerging as a broader immunotherapy opportunity. Driven by advances in bispecific antibodies, T-cell engagers (TCEs), and cellular therapies, CD79b is undergoing a transformation from a clinically validated target into a next-generation multimodal therapeutic target.

CD28: Unlocking T Cell Activation in Cancer

CD28 is becoming a key engineering node in next-generation T cell immunotherapy—not just a classical costimulatory receptor.
Recent insights show that PD-1–mediated inhibition converges mainly on the CD28 signaling axis, reshaping how we understand immune regulation and opening new design space for bispecific and multispecific therapies.
As CD28 moves from biology to therapeutic engineering, new questions are emerging around how to safely and precisely tune costimulatory signaling in the tumor microenvironment.
How far can CD28-directed engineering go in reshaping T cell responses?

TSHR: From an Endocrine Target to a Multi-Disease Therapeutic Platform

TSHR is emerging as a next-generation therapeutic target in autoimmune disease.
The field is shifting from symptom control toward upstream intervention, redefining how Graves’ disease and related disorders may be treated at their biological source.
This evolving landscape reflects a broader move toward precision, mechanism-driven therapies with cross-disease potential.
Discover how this transformation is reshaping the future of targeted treatment strategies.

CLDN18.2 Breakthrough: A New Dawn in Targeted Therapy for Gastric Cancer

IL-6: The Next Major Target in Inflammation Research

From major licensing deals and acquisitions to the emergence of long-acting and bispecific antibody strategies, IL-6 is attracting renewed attention across the biopharmaceutical industry. As its role expands beyond traditional inflammatory diseases, this well-established pathway may be entering a new phase of therapeutic innovation. Explore our latest article to learn why IL-6 is becoming one of the most closely watched targets in drug development.

ASCO 2026: Bispecific Antibodies Enter a New Phase of Immuno-Oncology Competition

First 1 2 3 4 5 Next Last

Total 8 Page

Jump

Current position：News > Insights

classify

Insights

CDH17: The Next Emerging Target in Gastrointestinal Cancer Therapy

Discover how CDH17 is emerging as a promising target in gastrointestinal cancer therapy and shaping the future of precision oncology.

BDCA2: The Next Frontier in Lupus Drug Development

By modulating plasmacytoid dendritic cell (pDC) activity and regulating type I interferon signaling, BDCA2-targeted therapies are opening new possibilities for autoimmune disease treatment.

CD117: A Classic Therapeutic Target Regaining Attention

Explore how CD117 (c-KIT), a classic therapeutic target, continues to inspire new research opportunities in the evolving landscape of drug discovery.

OX40/OX40L: Emerging Opportunities in Next-Generation Immunotherapy

Explore the emerging role of the OX40/OX40L signaling axis in next-generation immunotherapy, including its mechanisms of immune regulation, therapeutic potential, and evolving clinical landscape across oncology and autoimmune diseases.

CD79b: From ADC Success to the Next Frontier of Multimodal Immunotherapy

CD79b, once regarded primarily as an ADC target in B-cell malignancies, is now emerging as a broader immunotherapy opportunity. Driven by advances in bispecific antibodies, T-cell engagers (TCEs), and cellular therapies, CD79b is undergoing a transformation from a clinically validated target into a next-generation multimodal therapeutic target.

CD28: Unlocking T Cell Activation in Cancer

CD28 is becoming a key engineering node in next-generation T cell immunotherapy—not just a classical costimulatory receptor.
Recent insights show that PD-1–mediated inhibition converges mainly on the CD28 signaling axis, reshaping how we understand immune regulation and opening new design space for bispecific and multispecific therapies.
As CD28 moves from biology to therapeutic engineering, new questions are emerging around how to safely and precisely tune costimulatory signaling in the tumor microenvironment.
How far can CD28-directed engineering go in reshaping T cell responses?

TSHR: From an Endocrine Target to a Multi-Disease Therapeutic Platform

TSHR is emerging as a next-generation therapeutic target in autoimmune disease.
The field is shifting from symptom control toward upstream intervention, redefining how Graves’ disease and related disorders may be treated at their biological source.
This evolving landscape reflects a broader move toward precision, mechanism-driven therapies with cross-disease potential.
Discover how this transformation is reshaping the future of targeted treatment strategies.

CLDN18.2 Breakthrough: A New Dawn in Targeted Therapy for Gastric Cancer

IL-6: The Next Major Target in Inflammation Research

From major licensing deals and acquisitions to the emergence of long-acting and bispecific antibody strategies, IL-6 is attracting renewed attention across the biopharmaceutical industry. As its role expands beyond traditional inflammatory diseases, this well-established pathway may be entering a new phase of therapeutic innovation. Explore our latest article to learn why IL-6 is becoming one of the most closely watched targets in drug development.

ASCO 2026: Bispecific Antibodies Enter a New Phase of Immuno-Oncology Competition

MORE

Insights

Press Release

Contact
Us

Message Inquiry

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message Inquiry